Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000377484 | SCV000340089 | uncertain significance | not provided | 2016-03-14 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000377484 | SCV003833796 | uncertain significance | not provided | 2019-12-10 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003517173 | SCV004298807 | likely pathogenic | Bethlem myopathy 1A | 2024-07-06 | criteria provided, single submitter | clinical testing | This sequence change falls in intron 14 of the COL6A1 gene. It does not directly change the encoded amino acid sequence of the COL6A1 protein. It affects a nucleotide within the consensus splice site. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individual(s) with clinical features of autosomal dominant COL6A1-related conditions (PMID: 27447704, 30564623). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 286598). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |